Healthcare of Ontario Pension Plan Trust Fund Has $11.51 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Healthcare of Ontario Pension Plan Trust Fund trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 14.0% in the first quarter, HoldingsChannel reports. The institutional investor owned 34,781 shares of the biopharmaceutical company’s stock after selling 5,678 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Alnylam Pharmaceuticals were worth $11,508,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ALNY. MV Capital Management Inc. bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. HM Payson & Co. acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $27,000. Golden State Wealth Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the period. Finally, Manchester Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 600.0% in the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 72 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $288.41 on Wednesday. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 12 month low of $262.21 and a 12 month high of $495.55. The company has a fifty day simple moving average of $291.94 and a 200 day simple moving average of $314.22. The stock has a market cap of $38.51 billion, a P/E ratio of 78.80 and a beta of 0.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm’s revenue was up 96.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.44) EPS. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.35 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on ALNY. Wells Fargo & Company lifted their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Bank of America reduced their target price on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. HC Wainwright boosted their target price on Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Truist Financial lowered their price target on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a research note on Monday, July 13th. Finally, JPMorgan Chase & Co. cut their price target on shares of Alnylam Pharmaceuticals from $420.00 to $400.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $452.13.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.